Clinical Trial Update: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing zanubrutinib in combination with bendamustine/rituximab for newly diagnosed Waldenström's macroglobulinemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bendamustine/Rituximab
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Waldenström's Macroglobulinemia | Phase 2 | Status: UNKNOWN